Seelos Therapeutics Stock Performance
| SEEL Stock | USD 0.39 0.11 22.00% |
The entity has a beta of -4.28, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Seelos Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Seelos Therapeutics is expected to outperform it. At this point, Seelos Therapeutics has a negative expected return of -3.4%. Please make sure to validate Seelos Therapeutics' treynor ratio and the relationship between the skewness and price action indicator , to decide if Seelos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Seelos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 15.5 M |
Seelos |
Seelos Therapeutics Relative Risk vs. Return Landscape
If you would invest 319.00 in Seelos Therapeutics on September 18, 2024 and sell it today you would lose (280.00) from holding Seelos Therapeutics or give up 87.77% of portfolio value over 90 days. Seelos Therapeutics is currently does not generate positive expected returns and assumes 15.0767% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Seelos, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Seelos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seelos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Seelos Therapeutics, and traders can use it to determine the average amount a Seelos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2253
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SEEL |
Estimated Market Risk
| 15.08 actual daily | 96 96% of assets are less volatile |
Expected Return
| -3.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Seelos Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seelos Therapeutics by adding Seelos Therapeutics to a well-diversified portfolio.
Seelos Therapeutics Fundamentals Growth
Seelos OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Seelos Therapeutics, and Seelos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seelos OTC Stock performance.
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Price To Book | 15.10 X | |||
| Price To Sales | 0.37 X | |||
| Revenue | 2.2 M | |||
| EBITDA | (40.44 M) | |||
| Cash And Equivalents | 41.25 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 14.23 M | |||
| Debt To Equity | 0.73 % | |||
| Book Value Per Share | (135.50) X | |||
| Cash Flow From Operations | (23.91 M) | |||
| Earnings Per Share | 351.04 X | |||
| Total Asset | 5.42 M | |||
| Retained Earnings | (252.63 M) | |||
About Seelos Therapeutics Performance
By examining Seelos Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Seelos Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Seelos Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.Things to note about Seelos Therapeutics performance evaluation
Checking the ongoing alerts about Seelos Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Seelos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seelos Therapeutics is not yet fully synchronised with the market data | |
| Seelos Therapeutics generated a negative expected return over the last 90 days | |
| Seelos Therapeutics has high historical volatility and very poor performance | |
| Seelos Therapeutics has some characteristics of a very speculative penny stock | |
| Seelos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M). | |
| Seelos Therapeutics currently holds about 41.25 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. |
- Analyzing Seelos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seelos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seelos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seelos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seelos Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Seelos Therapeutics' otc stock. These opinions can provide insight into Seelos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.